Three High Profile Publications Support the Potential of Protagenic Therapeutics's Synthetic TCAP to Treat Stress-Related Psychological Disorders

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="http://www.globenewswire.com/styles/gnw_nitf.css" /><p></p><p align="center"><strong><em>Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology</em></strong></p><p></p><p align="justify">NEW YORK, June 11, 2018 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that the...